• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by RenovoRx Inc.

    2/14/22 6:33:04 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RNXT alert in real time by email
    SC 13G 1 formsc13g.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. __)*

     

     

    RENOVORX, INC.

    (Name of Issuer)

     

     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

     

    75989R 107

    (CUSIP Number)

     

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
     

     

    CUSIP No. 75989R 107

     

    1  

    NAME OF REPORTING PERSON:

     

    Kamran Najmabadi

       

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

     

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY:

     

    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION:

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    70,000

    6

    SHARED VOTING POWER

     

    975,000

    7

    SOLE DISPOSITIVE POWER

     

    70,000

    8

    SHARED DISPOSITIVE POWER

     

    975,000

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

     1,045,000(1)

    10  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS): ☐

     

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

     

    11.7%(2)

    12  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

     

    IN

     

    (1) Includes (i) 10,000 shares of common stock held of record by Kamran Najmabadi (the “Reporting Person”); (ii) 60,000 shares of common stock that are issuable upon exercise of outstanding options within 60 days of December 31, 2021 to the Reporting Person; (iii) 731,250 shares of common stock held of record by The Najmabadi Family Trust dated April 22, 2021 for which the Reporting Person serves as a trustee; (iv) 121,875 shares of common stock held of record by The Navid Najmabadi Irrevocable Trust dated April 22, 2021 for which the Reporting Person serves as a trustee; and (v) 121,875 shares of common stock held of record by The Leili Najmabadi Irrevocable Trust dated April 22, 2021 for which the Reporting Person serves as a trustee.

     

    (2) Based on 8,908,150 shares of the Issuer’s common stock outstanding as of November 1, 2021, as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021, filed with the Securities and Exchange Commission on November 15, 2021.

     

     
     

     

    CUSIP No. 75989R 107   Page 3

     

    1  

    NAME OF REPORTING PERSON:

     

    The Najmabadi Family Trust dated April 22, 2021

       

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

     

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY:

     

    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION:

     

    California

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    731,250

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    731,250

    8

    SHARED DISPOSITIVE POWER

     

    0

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

    731,250 (1)

    10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS): ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

     

    8.2% (2)

    12  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

     

    OO

     

    (1) The shares are held of record by The Najmabadi Family Trust dated April 22, 2021 for which Mr. Najmabadi serves as trustee.

     

    (2) Based on 8,908,150 shares of the Issuer’s common stock outstanding as of November 1, 2021, as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021, filed with the Securities and Exchange Commission on November 15, 2021.

     

     
     

     

    Item 1

     

    (a) Name of Issuer:

     

    RenovoRx, Inc.

     

    (b) Address of Issuer’s Principal Executive Offices:

     

    4546 El Camino Real, Suite B1

    Los Altos, California 94022

     

    Item 2

     

    (a) Names of Persons Filing:

     

    Each of the following is a reporting person (“Reporting Person”):

     

    Kamran Najmabadi

    The Najmabadi Family Trust dated April 22, 2021

     

    (b) Address or principal business office or, if none, residence:

     

    The address for the principal business office of the Reporting Persons is:

     

    c/o RenovoRx, Inc.

    4546 El Camino Real, Suite B1

    Los Altos, California 94022

     

    (c) Citizenship:

     

    Reference is made to the response to item 4 on each of pages 2 and 3 of this Schedule 13G (this “Schedule”), which responses are incorporated herein by reference.

     

    (d) Title and Class of Securities:

     

    Common Stock, par value $0.0001 per share.

     

    (e) CUSIP No.:

     

    75989R 107

     

    Item 3. If this statement is filed pursuant to Rules 13d-1(b) or 13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

    Item 4. Ownership

     

    Reference is hereby made to the responses to items 5-9 and 11 of pages 2 and 3 of this Schedule, which responses are incorporated herein by reference.

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    Not applicable.

     

    Item 6. Ownership of More than 5 Percent on Behalf of Another Person

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10. Certifications

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 11, 2022    
         
        /s/ Kamran Najmabadi
        Kamran Najmabadi

     

      THE NAJMABADI FAMILY TRUST DATED APRIL 22, 2021
         
      By: /s/ Kamran Najmabadi
      Name: Kamran Najmabadi
      Title: Trustee

     

     

     

     

     

    Get the next $RNXT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RNXT

    DatePrice TargetRatingAnalyst
    11/1/2021$16.00Buy
    Roth Capital
    10/6/2021$15.00Buy
    Maxim Group
    More analyst ratings

    $RNXT
    SEC Filings

    View All

    SEC Form 8-K filed by RenovoRx Inc.

    8-K - RenovoRx, Inc. (0001574094) (Filer)

    8/14/25 5:00:57 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by RenovoRx Inc.

    SCHEDULE 13G/A - RenovoRx, Inc. (0001574094) (Subject)

    8/14/25 4:42:08 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by RenovoRx Inc.

    10-Q - RenovoRx, Inc. (0001574094) (Filer)

    8/14/25 4:08:03 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNXT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Agah Ramtin bought $29,400 worth of shares (21,000 units at $1.40), increasing direct ownership by 3% to 734,460 units (SEC Form 4)

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    6/9/25 6:03:27 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Agah Ramtin bought $13,500 worth of shares (15,000 units at $0.90), increasing direct ownership by 1% to 1,113,460 units (SEC Form 4)

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    4/17/25 6:10:32 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Bagai Shaun bought $6,821 worth of shares (7,500 units at $0.91), increasing direct ownership by 2% to 320,040 units (SEC Form 4)

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    4/16/25 6:08:22 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNXT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review

    Revenue from RenovoCath® device totaled over $400,000 for the Second Quarter 2025 As of June 30, 2025, the Company had $12.3 million in cash and cash equivalents Management to host conference call today at 4:30 p.m. ET RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, today announced its financial results and business update to shareholders for the second quarter ended June 30, 2025. "We are pleased to report second quarter 2025 revenue of over $400,000. This growth highlights the strong clinical need and market demand for our

    8/14/25 4:05:00 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire

    RenovoRx increases its commercial footprint to thirteen leading National Cancer Institute-designated and community centers approved to purchase RenovoCath Four active cancer center customers are currently purchasing and have made repeat orders of RenovoCath for interventional radiology procedures RenovoRx hires Senior Director of Sales and Market Development to coordinate, execute, and expand commercialization strategy MOUNTAIN VIEW, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a patented, FDA-cleared drug-delivery devic

    8/6/25 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors

    Several Esteemed Cancer Centers to Commence Patient Enrollment Before the End of September The Registry Study, Known as PanTheR, will Expand the Safety and Performance Data of the FDA-Cleared RenovoCath® Device, and its Associated Survival Outcomes in Patients Diagnosed with Solid Tumors Cancer Centers in the Registry Study will Purchase RenovoCath Devices from RenovoRx RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a patented, FDA-cleared drug-delivery device, today announced the launch of the PanTheR Post-Marketing Registry Study (NCT06805461). The initiation of t

    7/28/25 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNXT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Executive Officer Bagai Shaun

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    7/3/25 4:45:33 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Medical Officer Agah Ramtin

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    7/3/25 4:45:34 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Clinical Officer Gentry Leesa

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    7/3/25 4:45:31 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNXT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on RenovoRx with a new price target

    Roth Capital initiated coverage of RenovoRx with a rating of Buy and set a new price target of $16.00

    11/1/21 11:49:10 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on RenovoRx with a new price target

    Maxim Group initiated coverage of RenovoRx with a rating of Buy and set a new price target of $15.00

    10/6/21 8:24:28 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNXT
    Financials

    Live finance-specific insights

    View All

    RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review

    Revenue from RenovoCath® device totaled over $400,000 for the Second Quarter 2025 As of June 30, 2025, the Company had $12.3 million in cash and cash equivalents Management to host conference call today at 4:30 p.m. ET RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, today announced its financial results and business update to shareholders for the second quarter ended June 30, 2025. "We are pleased to report second quarter 2025 revenue of over $400,000. This growth highlights the strong clinical need and market demand for our

    8/14/25 4:05:00 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET

    RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced it will host its second quarter 2025 financial results and business highlights conference call on August 14, 2025, at 4:30 p.m. ET. Additional details will be available in the Investor Relations section of the Company's website at https://ir.renovorx.com/. On the call, RenovoRx management is expected to discuss the latest developments and achievements for the Company's ongoing RenovoCath device commercialization efforts and for the Company's pivotal Phase III TIGeR-P

    7/14/25 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights

    Q1 2025 RenovoCath® Revenues of ~$200,000, Exceeding Expectations and Anticipated to Continue Growing Sequentially with New Customer Purchase Orders and Reorders Cash on Hand of $14.6 Million Anticipated to Fully Fund both RenovoCath Commercialization Scale-up and Continued Progress Towards the Completion of the Ongoing Phase III TIGeR-PaC Clinical Trial Completion of the TIGeR-PaC Clinical Trial Enrollment and Review of Second Interim Analysis by Data Monitoring Committee on Target for 2025 Company to Host Conference Call at 4:30 p.m. ET RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializ

    5/15/25 4:05:00 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNXT
    Leadership Updates

    Live Leadership Updates

    View All

    RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships

    LOS ALTOS, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that Ryan Witt has joined the Company in the new role as Senior Vice President, Head of Corporate Strategy and Partnerships. Mr. Witt's appointment highlights RenovoRx's commitment to explore and execute on clinical and commercial business development opportunities not only for its RenovoGem™ investigational combination product (currently in Phase III clinical development), but also opportunities with the Company's foundational FDA

    6/10/24 8:30:00 AM ET
    $IMMX
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RenovoRx Closes $6.1 Million Private Placement

    With Material Participation From Insiders, Offering Proceeds to Help Drive Company Towards Second Interim Analysis of the Pivotal TIGeR-PaC Phase III Clinical Trial by Late 2024 RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that it has closed a private placement (the "private placement" or the "financing") resulting in gross proceeds of approximately $6.1 million, before deducting offering expenses. The closing of this private placement extends RenovoRx's cash runway as RenovoRx continues its ongoing pivotal TIGeR-PaC Phase III c

    1/29/24 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D.

    RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced the appointment of Michel Ducreux, M.D., Ph.D. to the Company's Scientific Advisory Board (SAB). Dr. Ducreux is the Head of the Gastrointestinal Oncology Unit and Gastrointestinal Oncology Tumor Board at Gustave Roussy, Professor of Oncology at Paris-Saclay University in France, and Vice-Chair of ESMO GI. Dr. Ducreux was trained in medicine, gastroenterology, and gastrointestinal tract oncology at the University of Paris Sud. Dr. Ducreux earned his master's degree in biological sciences and PhD in health sciences. He has held pre

    11/16/23 8:35:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNXT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by RenovoRx Inc. (Amendment)

    SC 13G/A - RenovoRx, Inc. (0001574094) (Subject)

    2/14/23 4:51:34 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by RenovoRx Inc.

    SC 13G - RenovoRx, Inc. (0001574094) (Subject)

    4/14/22 2:24:24 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by RenovoRx Inc.

    SC 13G - RenovoRx, Inc. (0001574094) (Subject)

    2/14/22 6:33:04 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care